MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial
- PMID: 12114037
- DOI: 10.1016/S0140-6736(02)09328-5
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial
Abstract
Background: It has been suggested that increased intake of various antioxidant vitamins reduces the incidence rates of vascular disease, cancer, and other adverse outcomes.
Methods: 20,536 UK adults (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching placebo. Intention-to-treat comparisons of outcome were conducted between all vitamin-allocated and all placebo-allocated participants. An average of 83% of participants in each treatment group remained compliant during the scheduled 5-year treatment period. Allocation to this vitamin regimen approximately doubled the plasma concentration of alpha-tocopherol, increased that of vitamin C by one-third, and quadrupled that of beta-carotene. Primary outcomes were major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.
Findings: There were no significant differences in all-cause mortality (1446 [14.1%] vitamin-allocated vs 1389 [13.5%] placebo-allocated), or in deaths due to vascular (878 [8.6%] vs 840 [8.2%]) or non-vascular (568 [5.5%] vs 549 [5.3%]) causes. Nor were there any significant differences in the numbers of participants having non-fatal myocardial infarction or coronary death (1063 [10.4%] vs 1047 [10.2%]), non-fatal or fatal stroke (511 [5.0%] vs 518 [5.0%]), or coronary or non-coronary revascularisation (1058 [10.3%] vs 1086 [10.6%]). For the first occurrence of any of these "major vascular events", there were no material differences either overall (2306 [22.5%] vs 2312 [22.5%]; event rate ratio 1.00 [95% CI 0.94-1.06]) or in any of the various subcategories considered. There were no significant effects on cancer incidence or on hospitalisation for any other non-vascular cause.
Interpretation: Among the high-risk individuals that were studied, these antioxidant vitamins appeared to be safe. But, although this regimen increased blood vitamin concentrations substantially, it did not produce any significant reductions in the 5-year mortality from, or incidence of, any type of vascular disease, cancer, or other major outcome.
Comment in
-
Two decades of progress in preventing vascular disease.Lancet. 2002 Jul 6;360(9326):2-3. doi: 10.1016/S0140-6736(02)09358-3. Lancet. 2002. PMID: 12114031 No abstract available.
-
Antioxidant vitamins did not reduce death, vascular events, or cancer in high-risk patients.ACP J Club. 2003 Jan-Feb;138(1):3. ACP J Club. 2003. PMID: 12511115 No abstract available.
Summary for patients in
-
Antioxidants do not prevent heart disease in high-risk individuals.J Fam Pract. 2002 Oct;51(10):810. J Fam Pract. 2002. PMID: 12401142 No abstract available.
Similar articles
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. Lancet. 2002. PMID: 12114036 Clinical Trial.
-
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.Eur Heart J. 1999 May;20(10):725-41. doi: 10.1053/euhj.1998.1350. Eur Heart J. 1999. PMID: 10329064 Clinical Trial.
-
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7. Lancet. 2003. PMID: 12814710 Clinical Trial.
-
Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases.Curr Cardiol Rep. 2000 Jul;2(4):293-9. doi: 10.1007/s11886-000-0084-4. Curr Cardiol Rep. 2000. PMID: 10953262 Review.
-
Antioxidant vitamins and the prevention of coronary heart disease.Am Fam Physician. 1999 Sep 1;60(3):895-904. Am Fam Physician. 1999. PMID: 10498115 Review.
Cited by
-
Therapeutic Strategies for Oxidative Stress-Related Cardiovascular Diseases: Removal of Excess Reactive Oxygen Species in Adult Stem Cells.Oxid Med Cell Longev. 2016;2016:2483163. doi: 10.1155/2016/2483163. Epub 2016 Sep 7. Oxid Med Cell Longev. 2016. PMID: 27668035 Free PMC article. Review.
-
Pro-oxidant effect of alpha-tocopherol in patients with type 2 diabetes after an oral glucose tolerance test--a randomised controlled trial.Cardiovasc Diabetol. 2007 Feb 22;6:8. doi: 10.1186/1475-2840-6-8. Cardiovasc Diabetol. 2007. PMID: 17316429 Free PMC article. Clinical Trial.
-
Oxidative stress and heart disease: cardiac dysfunction, nutrition, and gene therapy.Curr Hypertens Rep. 2003 Jun;5(3):215-20. doi: 10.1007/s11906-003-0023-z. Curr Hypertens Rep. 2003. PMID: 12724053 Review.
-
Friend or Foe? The Roles of Antioxidants in Acute Lung Injury.Antioxidants (Basel). 2021 Dec 7;10(12):1956. doi: 10.3390/antiox10121956. Antioxidants (Basel). 2021. PMID: 34943059 Free PMC article. Review.
-
Vitamin/mineral supplementation and cancer, cardiovascular, and all-cause mortality in a German prospective cohort (EPIC-Heidelberg).Eur J Nutr. 2012 Jun;51(4):407-13. doi: 10.1007/s00394-011-0224-1. Epub 2011 Jul 22. Eur J Nutr. 2012. PMID: 21779961
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical